Follow Johnson & Johnson. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
52 Stories, 27 about Johnson & Johnson 4341 approved Programs 20784 recruiting Registered trials 10-Q Nov 16 Latest SEC filing Nov 13 Latest story
Timeline 27 Pipeline 43 Trials 207
Pipeline by stage
Approved 41 Phase 3 1 Other 1
Phase 3 primary completions, next 6 months
Dec 2026 polyradiculoneuropathy, chronic inflammatory demyelinating NCT05327114 All trials by completion date Details
Headquarters New Brunswick, NJ Incorporated New Jersey Industry Pharmaceutical Preparations Formerly JOHNSON & JOHNSON ET AL (to 1996) Also known as Actelion, Ambrx, J&J INNOVATIVE MEDICINE, Janssen, and 18 more Janssen Biotech, Janssen-Cilag, Janssen Pharmaceutica N.V., Belgium, Janssen Pharmaceutica NV, Janssen Pharmaceuticals, JANSSEN PHARMS, Janssen Products, LP, Janssen Research & Development, LLC, Janssen Sciences Ireland, Janssen Sciences Ireland Unlimited Company, JNJ, JOHNSON & JOHNSON ET AL, Johnson & Johnson Innovative Medicine, Johnson & Johnson Medical Korea Ltd, Johnson & Johnson Medical (Shanghai) Ltd., Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Johnson & Johnson Private Limited, Momenta PharmaceuticalsHow the company describes itself Johnson & Johnson develops pharmaceuticals, biologics, and medical devices across multiple therapeutic areas including oncology, immunology, cardiovascular disease, and infectious disease. source